360 High-Risk Vulnerability Immunization Tool V2.0 vs Siemba GenVA: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

Siemba GenVA: AI-powered vulnerability assessment engine for threat prioritization. built by Siemba. Core capabilities include AI-driven threat correlation mapping vulnerabilities to exploits and malware, Continuous vulnerability scanning with TCP/UDP and ICMP discovery, Automated finding grouping by severity, status, and confidence..

Both serve the Vulnerability Assessment market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Siemba GenVA differentiates with AI-driven threat correlation mapping vulnerabilities to exploits and malware, Continuous vulnerability scanning with TCP/UDP and ICMP discovery, Automated finding grouping by severity, status, and confidence.

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Siemba GenVA is developed by Siemba. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

360 High-Risk Vulnerability Immunization Tool V2.0 and Siemba GenVA serve similar Vulnerability Assessment use cases: both are Vulnerability Assessment tools. Review the feature comparison above to determine which fits your requirements.